Sawtooth Solutions LLC Cuts Stake in Gilead Sciences, Inc. (GILD)

Sawtooth Solutions LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 82.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,674 shares of the biopharmaceutical company’s stock after selling 12,824 shares during the period. Sawtooth Solutions LLC’s holdings in Gilead Sciences were worth $206,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Reilly Financial Advisors LLC raised its stake in shares of Gilead Sciences by 98.3% in the 3rd quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 704 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at $132,000. Brand Asset Management Group Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at $139,000. TRUE Private Wealth Advisors purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at $174,000. Finally, Truvestments Capital LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at $210,000. 78.23% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have recently commented on GILD. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, July 10th. ValuEngine downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Monday, August 20th. Mizuho set a $94.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, July 31st. Zacks Investment Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 25th. Finally, Cantor Fitzgerald raised their price target on shares of Gilead Sciences from $87.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, October 26th. Thirteen analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $87.84.

GILD opened at $69.44 on Friday. The firm has a market cap of $90.02 billion, a P/E ratio of 10.82, a PEG ratio of -2.69 and a beta of 1.01. Gilead Sciences, Inc. has a twelve month low of $64.27 and a twelve month high of $89.54. The company has a quick ratio of 3.39, a current ratio of 3.47 and a debt-to-equity ratio of 1.36.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.63 by $0.21. The business had revenue of $5.60 billion during the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same period last year, the business earned $2.27 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 6.44 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 3.28%. The ex-dividend date is Thursday, December 13th. Gilead Sciences’s dividend payout ratio is currently 26.64%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the completion of the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at approximately $239,408,146.48. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.30% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Recommended Story: How can you know how many shares are floating?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply